About
Daewoong Co., Ltd. generates revenue through its subsidiaries, each specializing in distinct sectors. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, and Hanall Biopharma Co Ltd manufacture and sell pharmaceuticals, targeting healthcare providers and consumers seeking medical treatments. Daewoong Development Co Ltd operates in real estate rental and supply, serving commercial and residential tenants. IDS&Trust Co Ltd produces communication-related devices for technology markets, while Daewoong Life Science Co Ltd focuses on food processing and sales for retail and food service segments. Pampaeg Co Ltd handles packaging for quasi-drugs, catering to pharmaceutical and wellness product distributors. Daewoong Management Development Institute Co Ltd provides management and industrial training services to corporate clients. The company's revenue streams are diversified across pharmaceutical manufacturing, real estate services, communication devices, food processing, quasi-drug packaging, and corporate training. Pharmaceutical subsidiaries dominate the revenue mix, serving both institutional and consumer markets. Real estate operations contribute through long-term rental agreements, while communication device sales target technology-focused businesses. Food processing and quasi-drug packaging align with health and wellness industry demands, and training services support corporate workforce development. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, and Hanall Biopharma Co Ltd are key revenue drivers in the pharmaceutical sector, selling directly to hospitals, pharmacies, and consumers. Daewoong Development Co Ltd leases properties to businesses and individuals, generating steady rental income. IDS&Trust Co Ltd supplies communication devices to tech companies and service providers. Daewoong Life Science Co Ltd distributes processed food products through retail channels, and Pampaeg Co Ltd packages quasi-drugs for pharmaceutical firms. Training services from Daewoong Management Development Institute Co Ltd are contracted by corporations for employee development programs.
Annual results
Reported figures, KRW · revenue up 6.8% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 2.1T | 175B | 8.5% | — |
| 2024 | 1.9T | 57.9B | 3.0% | — |
| 2023 | 1.8T | 153B | 8.4% | — |
| 2022 | 1.7T | 103B | 6.0% | — |
| 2021 | 1.5T | 78.8B | 5.2% | — |
Dividends per share
003090.KS in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Daewoong Co Ltd are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.